ENTITY

SpyGlass Pharma (SGP US)

9
Analysis
Health Care • United States
Spyglass Pharma, Inc. operates as an ophthalmic biotechnology company. The company provides drug delivery platform, lasting treatment, and routine ophthalmic surgery. Spyglass Pharma serves glaucoma patients worldwide.
more
bullish•SpyGlass Pharma
•05 Aug 2026 20:38

SpyGlass Pharma (SGP US): Synthetic Expert Call Transcript (05 Aug 2026)

Zero Workflow Friction is the Core Adoption Catalyst: Unlike micro-invasive glaucoma surgery (MIGS) or other drug-eluting platforms, SpyGlass...

Share
bullish•SpyGlass Pharma
•05 Aug 2026 13:00

SpyGlass Pharma (SGP): Six Months Later: Strong Debut Holds Above Water as Investors Await Data

​SpyGlass Pharma's strong IPO debut reflects high demand for its innovative glaucoma and cataract treatment platform, with potential for future...

Logo
107 Views
Share
bullish•SpyGlass Pharma
•07 Feb 2026 05:25

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

​SpyGlass Pharma's IPO priced at $16.00, closed at $26.40 (+65%), oversubscribed deal with strong investor support, backed by top-tier investors...

Logo
311 Views
Share
bullish•SpyGlass Pharma
•03 Feb 2026 13:10

SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

​SpyGlass Pharma's oversubscribed IPO offers innovative BIM-IOL System for cataract surgery with glaucoma treatment, backed by top investors and...

Logo
443 Views
Share
bullish•SpyGlass Pharma
•03 Feb 2026 12:33

IPO Rating: Spyglass Pharma Inc.

✅ IPO PROPHET RATING: 7.6/10 🏦 Deal Quality & Underwriters: 8.2/10 Spyglass Therapeutics is preparing to list on the Nasdaq under the ticker...

Logo
270 Views
Share
x